)

FibroBiologics (FBLG) investor relations material
FibroBiologics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Focused on developing fibroblast-based therapies for chronic diseases, with lead candidates in wound healing, multiple sclerosis, degenerative disc disease, and psoriasis; no product revenue to date.
Completed preclinical studies for CYWC628 and CYMS101, with a Phase 1/2 trial for diabetic foot ulcers in Australia planned for Q1 2026.
Formed an Australian subsidiary to sponsor clinical trials and completed manufacturing of master and working cell banks for CYWC628.
Closed third $5 million tranche of $25 million financing to fund R&D and clinical trials.
Appointed new CFO with over 25 years of experience and engaged a consultant for strategic advisory and capital raising support.
Financial highlights
Net loss of $4.7 million for Q2 2025 and $9.6 million for the six months ended June 30, 2025, compared to $0.9 million net income and $7.6 million net loss in prior year periods.
Operating expenses increased to $4.5 million in Q2 2025 from $3.2 million in Q2 2024, driven by higher R&D and administrative costs.
Research and development expenses rose to $3.8 million for the six months ended June 30, 2025, up from $1.9 million year-over-year.
General and administrative expenses were $2.4 million in Q2 2025 and $5.2 million for the six months ended June 30, 2025.
Cash and cash equivalents were $8.8 million as of June 30, 2025, down from $14.0 million at year-end 2024.
Outlook and guidance
Expects to continue incurring significant losses as R&D and clinical activities expand; no product revenue anticipated in the near term.
Plans to initiate a Phase 1/2 clinical trial for CYWC628 in Australia in Q1 2026, with completion targeted for Q3 2026, pending resolution of manufacturing issues.
Pre-clinical IND-enabling studies for psoriasis treatment CYPS317 to be completed by end of 2025.
Ongoing need for additional capital to fund operations; substantial doubt exists about ability to continue as a going concern without further financing.
Next FibroBiologics earnings date

Next FibroBiologics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage